These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37493758)

  • 1. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].
    Kaudewitz D; Lorenz HM
    Inn Med (Heidelb); 2023 Oct; 64(10):1005-1012. PubMed ID: 37493758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK Inhibitors: What Is New?
    Reddy V; Cohen S
    Curr Rheumatol Rep; 2020 Jul; 22(9):50. PubMed ID: 32700001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan.
    Kaneko Y; Sakurai M; Snijder R; Kokubo S; Kato D
    Mod Rheumatol; 2023 Apr; 33(3):448-459. PubMed ID: 35640001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
    Yamaoka K
    Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome.
    Tanaka Y
    Expert Opin Pharmacother; 2023; 24(16):1791-1798. PubMed ID: 37563102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk profile of disease-modifying antirheumatic drugs: an update from the RABBIT register].
    Albrecht K; Strangfeld A
    Dtsch Med Wochenschr; 2021 Aug; 146(15):998-1002. PubMed ID: 34344036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 14. [What is certain in the treatment of rheumatoid arthritis?].
    Witte T
    Internist (Berl); 2018 Dec; 59(12):1249-1254. PubMed ID: 30276426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Janus kinase inhibitors].
    Witte T
    Z Rheumatol; 2022 Mar; 81(2):94-99. PubMed ID: 34820733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
    Tanaka Y
    Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi12-vi20. PubMed ID: 34951925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire.
    Beauvais C; Gaud-Listrat V; Sellam J; Fayet F; Béranger M; Deparis N; Antignac M; Sordet C; Rodère M; Gossec L
    Joint Bone Spine; 2021 Oct; 88(5):105215. PubMed ID: 33992790
    [No Abstract]   [Full Text] [Related]  

  • 18. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
    Sonomoto K; Tanaka Y
    Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
    Kotyla PJ; Islam MA; Engelmann M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
    Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.